Notice of Annual Results and analyst briefing
LONDON, 16 April, 2018: Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, will announce its annual results for the period ended 31 December 2017 on Monday 23 April 2018.
Joe Anderson, Chief Executive Officer, and James Rawlingson, Chief Financial Officer, will host a lunch briefing and call for analysts at 12:00 BST on the day of the results at Stifel, 150 Cheapside, London, EC2V 6ET.
Details of the call will be available on request. The call will be recorded and a replay will be available on Arix's website.
- ENDS -
For more information, please contact:
Arix Bioscience plc
Charlotte Parry, Investor Relations Manager
+44 (0)20 7290 1072
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com
This information is provided by RNS